

Supplementary Table 1

Timing of BG (mmol/L)	Placebo (n=18)	Metformin (n=18)	Liraglutide (n=18)
Baseline before HFD	6.7 ± 0.3	5.6 ± 0.18	6.2 ± 0.67
1 mo after HFD and before STZ exposure	7.17 ± 0.27	7.41 ± 0.35	7.98 ± 0.36
After STZ and before drug treatment	18.25 ± 0.9	18.88 ± 1.054	19.64 ± 1.1
1 wk after drug treatment	21.3 ± 0.8	8.57 ± 0.67	7.85 ± 0.56
1 mo after LAD ligation	23.55 ± 0.9	25.5 ± 1.3	21.66 ± 2.06

Random tail blood glucose (BG) levels in mice employed for generating the high fat diet (HFD)- and streptozotocin (STZ)- model of diabetes. Data are expressed as mean ± SE. No significant differences were observed in liraglutide vs. metformin-treated groups at any time-points. Although body weight did not change in MET-treated animals (d0: 27.3±0.5 vs. d7: 27.5 ± 0.4, g, P=0.72), LIR 75-treated diabetic mice experienced modest weight loss (d0: 26.7 ± 0.5 vs. d7: 24.9 ± 0.7, g, P=0.04).

Experimental design

Supplementary Figure 1

